ACR 2026 Congress Library Resources | AZ US

American College of Rheumatology (ACR) Convergence 2026

November 6 - 11, 2026

All
Saphnelo (Anifrolumab)
Immunology Unbranded
FASENRA (benralizumab)

HTML

Reduced Glucocorticoid Use in Patients With SLE Receiving Intravenous/Subcutaneous Anifrolumab Versus Placebo: Pooled Data From Phase 3 Clinical Trials

HTML

Efficacy of Anifrolumab Treatment in Improving Joint Outcomes: Pooled Data from Intravenous and Subcutaneous Phase 3 Trials

HTML

Efficacy and safety outcomes of real-world off label anifrolumab use in CLE with or without concomitant SLE: a systematic literature review

HTML

Anifrolumab Treatment Prevents Long-Term Oral Corticosteroid-Related, Ocular, and Musculoskeletal Organ Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study

HTML

Indirect Treatment Comparison of Efficacy of Subcutaneous Anifrolumab Versus Intravenous Anifrolumab in Patients With Systemic Lupus Erythematosus

HTML

Glucocorticoid Dose Reduction and Low Flare Rates in Patients With SLE Receiving Anifrolumab in Routine Practice: 12-Month Interim Analysis of a Multinational Observational Real-World Study

HTML

Patient-Reported Outcomes After 12 Months of Real-World Anifrolumab Treatment: Interim Results From a Multinational, Real-World Study

HTML

Treatment Adherence in Patients with SLE Receiving Anifrolumab in Routine Practice: 12-Month Interim Analysis of a Multinational Observational Real-World Study

HTML

Anifrolumab Treatment is Associated With DORIS-Zero Remission in Adults With Systemic Lupus Erythematosus: Real-World Outcomes From an Academic Lupus Registry

HTML

Anifrolumab Treatment is Associated With Lupus Low Disease Activity State in Adults With Systemic Lupus Erythematosus: Real-World Outcomes From an Academic Lupus Registry

HTML

Assessment of Renal, Hematological, and Immunological Lab Values Among Patients Diagnosed With Systemic Lupus Erythematosus Pre- and Post-Anifrolumab Treatment Initiation: A Large Real-World Analysis

HTML

Organ-Specific Treatment Response: Real-World Mucocutaneous and Musculoskeletal Outcomes After 6 and 12 Months of Anifrolumab Treatment

HTML

Improvements in SLE Disease Activity Across Multiple Organ Systems with Intravenous and Subcutaneous Anifrolumab Treatment: Pooled Analysis of 3 Phase 3 Trials

HTML

Population Pharmacokinetics and Exposure-Response Analyses of Subcutaneous and Intravenous Anifrolumab in Patients with Systemic Lupus Erythematosus

HTML

Real-World Glucocorticoid Treatment Patterns and Utilization in Adults with SLE: A Global Systematic Literature Review

HTML

Association between daily dose of oral glucocorticoids and infections in patients with eosinophilic granulomatosis with polyangiitis treated with anti-interleukin-5/receptor therapies

HTML

Adverse events associated with the use of glucocorticoids in patients with eosinophilic granulomatosis with polyangiitis

HTML

Unmet treatment needs in eosinophilic granulomatosis with polyangiitis (EGPA): real-world rheumatology and multispecialty care patterns in the United States

HTML

IL-33 blockade limits gut-joint trafficking of IL-17A-producing MAIT, Th17 and TRM cells in experimental spondyloarthritis

HTML

Reduced Glucocorticoid Use in Patients With SLE Receiving Intravenous/Subcutaneous Anifrolumab Versus Placebo: Pooled Data From Phase 3 Clinical Trials

HTML

Efficacy of Anifrolumab Treatment in Improving Joint Outcomes: Pooled Data from Intravenous and Subcutaneous Phase 3 Trials

HTML

Efficacy and safety outcomes of real-world off label anifrolumab use in CLE with or without concomitant SLE: a systematic literature review

HTML

Anifrolumab Treatment Prevents Long-Term Oral Corticosteroid-Related, Ocular, and Musculoskeletal Organ Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study

HTML

Indirect Treatment Comparison of Efficacy of Subcutaneous Anifrolumab Versus Intravenous Anifrolumab in Patients With Systemic Lupus Erythematosus

HTML

Glucocorticoid Dose Reduction and Low Flare Rates in Patients With SLE Receiving Anifrolumab in Routine Practice: 12-Month Interim Analysis of a Multinational Observational Real-World Study

HTML

Patient-Reported Outcomes After 12 Months of Real-World Anifrolumab Treatment: Interim Results From a Multinational, Real-World Study

HTML

Treatment Adherence in Patients with SLE Receiving Anifrolumab in Routine Practice: 12-Month Interim Analysis of a Multinational Observational Real-World Study

HTML

Anifrolumab Treatment is Associated With DORIS-Zero Remission in Adults With Systemic Lupus Erythematosus: Real-World Outcomes From an Academic Lupus Registry

HTML

Anifrolumab Treatment is Associated With Lupus Low Disease Activity State in Adults With Systemic Lupus Erythematosus: Real-World Outcomes From an Academic Lupus Registry

HTML

Assessment of Renal, Hematological, and Immunological Lab Values Among Patients Diagnosed With Systemic Lupus Erythematosus Pre- and Post-Anifrolumab Treatment Initiation: A Large Real-World Analysis

HTML

Organ-Specific Treatment Response: Real-World Mucocutaneous and Musculoskeletal Outcomes After 6 and 12 Months of Anifrolumab Treatment

HTML

Improvements in SLE Disease Activity Across Multiple Organ Systems with Intravenous and Subcutaneous Anifrolumab Treatment: Pooled Analysis of 3 Phase 3 Trials

HTML

Population Pharmacokinetics and Exposure-Response Analyses of Subcutaneous and Intravenous Anifrolumab in Patients with Systemic Lupus Erythematosus

HTML

Real-World Glucocorticoid Treatment Patterns and Utilization in Adults with SLE: A Global Systematic Literature Review

HTML

Adverse events associated with the use of glucocorticoids in patients with eosinophilic granulomatosis with polyangiitis

HTML

Unmet treatment needs in eosinophilic granulomatosis with polyangiitis (EGPA): real-world rheumatology and multispecialty care patterns in the United States

HTML

IL-33 blockade limits gut-joint trafficking of IL-17A-producing MAIT, Th17 and TRM cells in experimental spondyloarthritis

HTML

Association between daily dose of oral glucocorticoids and infections in patients with eosinophilic granulomatosis with polyangiitis treated with anti-interleukin-5/receptor therapies

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved. 
US-107328
Last Updated 5/26

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences